mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.064 |
0.09 |
mRNA |
crizotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.058 |
0.09 |
mRNA |
hyperforin |
CTRPv2 |
pan-cancer |
AAC |
0.065 |
0.09 |
mRNA |
AKT inhibitor VIII |
GDSC1000 |
pan-cancer |
AAC |
-0.056 |
0.09 |
mRNA |
Talazoparib |
GDSC1000 |
pan-cancer |
AAC |
-0.055 |
0.09 |
mRNA |
marinopyrrole A |
CTRPv2 |
pan-cancer |
AAC |
0.074 |
0.1 |
mRNA |
CD-1530 |
CTRPv2 |
pan-cancer |
AAC |
0.064 |
0.1 |
mRNA |
linifanib |
GDSC1000 |
pan-cancer |
AAC |
0.057 |
0.1 |
mRNA |
BRD-K96970199 |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.1 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.061 |
0.1 |